By Advocate.com Editors
Originally published on Advocate.com January 15 2003 12:00 AM ET
Immune Response Corp., maker of the experimental HIV vaccine Remune, last week announced the appointment of John Bonfiglio as the company's new chief executive officer. He will be charged with spearheading the company's development of Remune, currently in clinical trials for possible use in combination with antiretroviral drugs to slow or stop HIV replication in people infected with the virus.
"A significant factor in any HIV treatment development is the importance of the HIV activist and medical communities, whose long-term advocacy and input have been instrumental in the advancement of new treatments," Bonfiglio said. "I look forward to working closely with these groups as we pursue the ongoing development of Remune."